These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 30305507

  • 1. [Myelodysplastic syndromes and iron metabolism].
    Kawabata H.
    Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
    [Abstract] [Full Text] [Related]

  • 2. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N.
    Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
    [Abstract] [Full Text] [Related]

  • 3. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y.
    Blood; 2014 Aug 07; 124(6):873-81. PubMed ID: 24923296
    [Abstract] [Full Text] [Related]

  • 4. Iron overload in myelodysplastic syndromes.
    Mahesh S, Ginzburg Y, Verma A.
    Leuk Lymphoma; 2008 Mar 07; 49(3):427-38. PubMed ID: 18297518
    [Abstract] [Full Text] [Related]

  • 5. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.
    Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M.
    Sci Transl Med; 2019 Jul 10; 11(500):. PubMed ID: 31292266
    [Abstract] [Full Text] [Related]

  • 6. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
    Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S.
    Leuk Res; 2017 Nov 10; 62():108-115. PubMed ID: 29054020
    [Abstract] [Full Text] [Related]

  • 7. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y, Li X, Chang C, Xu F, He Q, Guo J, Tao Y, Liu Y, Liu L, Shi W.
    Leuk Res; 2016 May 10; 44():8-16. PubMed ID: 26970172
    [Abstract] [Full Text] [Related]

  • 8. Iron overload in patients with myelodysplastic syndromes: An updated overview.
    Moukalled NM, El Rassi FA, Temraz SN, Taher AT.
    Cancer; 2018 Oct 15; 124(20):3979-3989. PubMed ID: 29905937
    [Abstract] [Full Text] [Related]

  • 9. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F, Phatak P.
    Expert Rev Hematol; 2017 Jan 15; 10(1):53-64. PubMed ID: 27923273
    [Abstract] [Full Text] [Related]

  • 10. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
    Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, Huang G, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z.
    Leuk Res; 2014 May 15; 38(5):545-50. PubMed ID: 24598841
    [Abstract] [Full Text] [Related]

  • 11. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA.
    Drugs; 2011 Jan 22; 71(2):155-77. PubMed ID: 21275444
    [Abstract] [Full Text] [Related]

  • 12. EnvIRONmental Aspects in Myelodysplastic Syndrome.
    Petzer V, Theurl I, Weiss G, Wolf D.
    Int J Mol Sci; 2021 May 14; 22(10):. PubMed ID: 34068996
    [Abstract] [Full Text] [Related]

  • 13. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
    Steensma DP, Gattermann N.
    Best Pract Res Clin Haematol; 2013 Dec 14; 26(4):431-44. PubMed ID: 24507819
    [Abstract] [Full Text] [Related]

  • 14. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
    Zeidan AM, Pullarkat VA, Komrokji RS.
    Crit Rev Oncol Hematol; 2017 Sep 14; 117():57-66. PubMed ID: 28807236
    [Abstract] [Full Text] [Related]

  • 15. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
    Cuijpers ML, Raymakers RA, Mackenzie MA, de Witte TJ, Swinkels DW.
    Br J Haematol; 2010 May 14; 149(3):322-33. PubMed ID: 20067561
    [Abstract] [Full Text] [Related]

  • 16. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J, Kurtin SE, Arnold L, Lindroos-Kolqvist P, Tinsley S.
    Clin J Oncol Nurs; 2012 Jun 14; 16 Suppl():37-46. PubMed ID: 22641283
    [Abstract] [Full Text] [Related]

  • 17. Iron overload in patients with myelodysplastic syndromes.
    Jensen PD.
    Curr Hematol Malig Rep; 2007 Feb 14; 2(1):13-21. PubMed ID: 20425384
    [Abstract] [Full Text] [Related]

  • 18. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
    Cazzola M, Della Porta MG, Malcovati L.
    Hematology Am Soc Hematol Educ Program; 2008 Feb 14; ():166-75. PubMed ID: 19074076
    [Abstract] [Full Text] [Related]

  • 19. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA, Vickars LM.
    Hematology Am Soc Hematol Educ Program; 2009 Feb 14; ():664-72. PubMed ID: 20008252
    [Abstract] [Full Text] [Related]

  • 20. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S, Santini V, Musallam K, Taher A.
    Crit Rev Oncol Hematol; 2014 Jul 14; 91(1):64-73. PubMed ID: 24529413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.